- Home
- RXRX vs OGN Comparison
RXRX vs OGN Comparison
Compare RXRX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- OGN
- Stock Information
- Founded
- RXRX 2013
- OGN 1923
- Country
- RXRX United States
- OGN United States
- Employees
- RXRX N/A
- OGN N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- OGN Health Care
- Exchange
- RXRX Nasdaq
- OGN Nasdaq
- Market Cap
- RXRX 2.4B
- OGN 2.5B
- IPO Year
- RXRX 2021
- OGN N/A
- Fundamental
- Price
- RXRX $5.77
- OGN $9.43
- Analyst Decision
- RXRX Buy
- OGN Hold
- Analyst Count
- RXRX 5
- OGN 4
- Target Price
- RXRX $7.00
- OGN $18.00
- AVG Volume (30 Days)
- RXRX 24.9M
- OGN 4.6M
- Earning Date
- RXRX 08-05-2025
- OGN 08-05-2025
- Dividend Yield
- RXRX N/A
- OGN 0.85%
- EPS Growth
- RXRX N/A
- OGN N/A
- EPS
- RXRX N/A
- OGN 2.69
- Revenue
- RXRX $64,596,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- RXRX $19.96
- OGN N/A
- Revenue Next Year
- RXRX $61.39
- OGN $1.02
- P/E Ratio
- RXRX N/A
- OGN $3.51
- Revenue Growth
- RXRX 30.14
- OGN N/A
- 52 Week Low
- RXRX $3.79
- OGN $8.01
- 52 Week High
- RXRX $12.36
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- RXRX 53.41
- OGN 48.65
- Support Level
- RXRX $5.41
- OGN $8.93
- Resistance Level
- RXRX $5.82
- OGN $9.43
- Average True Range (ATR)
- RXRX 0.32
- OGN 0.48
- MACD
- RXRX -0.04
- OGN 0.00
- Stochastic Oscillator
- RXRX 52.78
- OGN 53.59
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.